Phosphorylation of Rad9 at Serine 328 by Cyclin A-Cdk2 Triggers Apoptosis via Interfering Bcl-xL

Zhuo Zhan1,2, Kan He1, Dan Zhu1, Dan Jiang1, Ying-Hui Huang3, Yang Li1, Chao Sun1, Ying-Hua Jin1,2*

1 Key Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, College of Life Science, Jilin University, Changchun, China, 2 State Key Laboratory of Supramolecular Structure & Materials, Jilin University, Changchun, China, 3 Cancer Center, China-Japan Union Hospital, Jilin University, Changchun, China

Abstract

Cyclin A-Cdk2, a cell cycle regulated Ser/Thr kinase, plays important roles in a variety of apoptotic processes. However, the mechanism of cyclin A-Cdk2 regulated apoptosis remains unclear. Here, we demonstrated that Rad9, a member of the BH3-only subfamily of Bcl-2 proteins, could be phosphorylated by cyclin A-Cdk2 in vitro and in vivo. Cyclin A-Cdk2 catalyzed the phosphorylation of Rad9 at serine 328 in HeLa cells during apoptosis induced by etoposide, an inhibitor of topoisomerase II. The phosphorylation of Rad9 resulted in its translocation from the nucleus to the mitochondria and its interaction with Bcl-xL. The forced activation of cyclin A-Cdk2 in these cells by the overexpression of cyclin A triggered Rad9 phosphorylation at serine 328 and thereby promoted the interaction of Rad9 with Bcl-xL and the subsequent initiation of the apoptotic program. The pro-apoptotic effects regulated by the cyclin A-Cdk2 complex were significantly lower in cells transfected with Rad9S328A, an expression vector that encodes a Rad9 mutant that is resistant to cyclin A-Cdk2 phosphorylation. These findings suggest that cyclin A-Cdk2 regulates apoptosis through a mechanism that involves Rad9 phosphorylation.

Citation: Zhan Z, He K, Zhu D, Jiang D, Huang Y-H, et al. (2012) Phosphorylation of Rad9 at Serine 328 by Cyclin A-Cdk2 Triggers Apoptosis via Interfering Bcl-xL. PLoS ONE 7(9): e44923. doi:10.1371/journal.pone.0044923

Editor: Tetuho Takehara, Osaka University Graduate School of Medicine, Japan

Received June 6, 2012; Accepted August 9, 2012; Published September 13, 2012

Copyright: © 2012 Zhan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: yhjin@jlu.edu.cn

Introduction

Cyclin A-Cdk2, a cell cycle regulated Ser/Thr kinase, regulates mammalian cell cycle progression by phosphorylating specific substrates during S phase [1,2]. There is increasing evidence that cyclin A-Cdk2 also plays an important role in apoptosis. Cdk2 activation has been observed in the apoptosis of ultraviolet irradiated mesangial cells [3], etoposide-treated human leukemia cells [4,5], growth factor-deprived HUV-EC cells [6], ginsenoside-Rh2 (G-Rh2)-treated human hepatoma cells [7], panaxadiol-treated SK-HEP-1 cells [8], and paclitaxel-treated HeLa cells [9]. We showed previously that Cdk2 activity, but not Cdc2 activity, was selectively up-regulated in paclitaxel-treated HeLa cells [9]. We showed previously that Cdk2 activity, but not Cdc2 activity, was selectively up-regulated in paclitaxel-treated HeLa cells [9]. We showed previously that Cdk2 activity, but not Cdc2 activity, was selectively up-regulated in paclitaxel-treated HeLa cells [9]. We showed previously that Cdk2 activity, but not Cdc2 activity, was selectively up-regulated in paclitaxel-treated HeLa cells [9].

Studies of apoptosis suggest that Bcl-2 family proteins regulate the permeabilization of mitochondri al outer membrane (PMOM) and the release of cytochrome c. Anti-apoptotic Bcl-2 family members function to block PMOM, whereas the multidomain pro-apoptotic molecules Bax and Bak serve as obligatory effectors of cytochrome c release in response to diverse stimuli. The other subfamily, the BH3-only proteins (which contain only the BH3 domain), can either interfere with the anti-apoptotic Bcl-2 family memberson activate Bax and Bak [10–14].

The Rad9 gene was firstly isolated from the fission yeast Schizosaccharomyces pombe (S. pombe) by functional complementation of the radiosensitivity of corresponding mutant cells [15]. Later studies showed that the human Rad9 gene was evolutionarily conserved and played important roles in many fundamental biological processes, including the maintenance of genome stability, the control of cell cycle checkpoints, the promotion of resistance to DNA damage, and the promotion of apoptosis [16–21]. Rad9 can bind to Rad1 and Hus1 to form a heterotrimetric complex (the 9-1-1 complex) [22–25], and it is believed to perform many of its surveillance activities as part of this 9-1-1 heterotrimer. Other studies have shown that Rad9 contains a Bcl-2 homology (BH3)-like domain that is typical of BH3-only pro-apoptotic family members and that the overexpression of Rad9 in a variety of human cell lines induces apoptosis [26,27]. Rad9 phosphorylation at tyrosine 28 by c-Abl in U-937 cells is induced by UV irradiation, and the phosphorylation of Rad9 by protein kinase C8 (PKC8) enhances the association of Rad9 with Bcl-2 [28,29].

Here, we show that Rad9 is a novel substrate for cyclin A-Cdk2 under apoptotic conditions. Cyclin A-Cdk2 phosphorylated Rad9 at serine 328 in HeLa cells during apoptosis induced by the treatment of etoposide, an inhibitor of topoisomerase II. The phosphorylation of Rad9 promoted its translocation to mitochondria and enhanced its interaction with Bcl-xL. The ectopic expression of Rad9 and cyclin A dramatically increased Rad9 triggered apoptosis. Taken together, these findings suggest that Rad9 is a novel substrate for cyclin A-Cdk2 under apoptotic conditions and mediates apoptotic signaling from cyclin A-Cdk2 to the mitochondria.
Results

Rad9 is Phosphorylated by Cyclin A-Cdk2 in vitro and in vivo

Previous studies have shown that cyclin A-Cdk2 activity is required for apoptosis induced by diverse stimuli [3–9]. Because cyclin A-Cdk2 is a protein kinase, we considered the possibility that it might promote apoptosis by directly phosphorylating and thereby activating a component of the cell death regulatory machinery. Rad9 is a phosphoprotein that can be phosphorylated by a number of kinases under specific conditions [30]. Rad9 is a BH3-only protein, and it can trigger apoptosis by inhibiting the anti-apoptotic proteins Bcl-2 and Bcl-XL [26]. To determine whether Rad9 is phosphorylated by cyclin A-Cdk2, we performed an in vitro kinase assay. Cyclin A-Cdk2 was immunoprecipitated using a Cdk2 antibody from etoposide-treated HeLa cells and induced strong phosphorylation of recombinant GST-Rad9 in a time-dependent manner; this Rad9 phosphorylation was markedly reduced in the presence of roscovitine, an inhibitor of Cdk2 (Fig. 1A). To determine whether Rad9 phosphorylation also occurs in cells, HeLa cells were co-transfected with pCMV-Cyclin A or pCMV-Cdk2-dn with pCS4+Rad9, and Rad9 phosphorylation was assayed. We showed previously that the overexpression of cyclin A strongly activated Cdk2 in a dose-dependent manner and that the overexpression of Cdk2-dn inhibited Cdk2 activity [7]. In the present study, Rad9 phosphorylation status was characterized by analyzing its electrophoretic mobility. Immunoblotting analysis with an anti-Rad9 antibody showed that the slower-migrating (i.e., phosphorylated) form of Rad9 was clearly enhanced in cyclin A overexpression (Fig. 1B). These findings demonstrate that cyclin A-Cdk2 phosphorylates Rad9 in vitro and in vivo.

Rad9 is Phosphorylated by cyclin A-Cdk2 in Etoposide-treated HeLa Cells

Previously, studies have shown that cyclin A-Cdk2 activity but not cdc2 activity was up-regulated during apoptosis induced by etoposide treatment [4]. To determine whether Rad9 is phosphorylated by cyclin A-Cdk2 in etoposide-treated apoptotic cells, we first examined the phosphorylation status of Rad9 by immunoblotting with anti-Rad9 antibodies. Apoptosis was monitored by examining cell morphology and caspase activity. Individual cells exhibited several morphological changes that typically occur during apoptosis, such as cell rounding and membrane blebbing, after treatment for 16 h (Fig. 2A). PARP, a well-known caspase-3 substrate, was cleaved to yield 85 kD fragment 16 h after the treatment of HeLa cells with etoposide (Fig. 2B). The electrophoretic mobility of Rad9 was clearly shifted beginning at 4 h post etoposide treatment, indicating that Rad9 phosphorylation may have occurred at an early stage of etoposide-induced apoptosis in HeLa cells (Fig. 2C). The levels of cyclin A (Fig. 2C) and of cyclin A-Cdk2 activity (Fig. 2D) were up-regulated in a etoposide treating time-dependent manner.

Next, we examined whether cyclin A-Cdk2 phosphorylates Rad9 in etoposide-treated HeLa cells. Immunoblot analyses of immunocomplexes that were immunoprecipitated from HeLa cells by specific anti-Rad9 antibody demonstrated that both cyclin A and Cdk2 interacted with Rad9 after the cells were treated with etoposide for 8 h (Fig. 3B). To identify the phosphorylation site within Rad9, we performed immunoblotting analyses using phospho-specific antibodies against phospho328-Rad9, phospho277-Rad9, and phospho336-Rad9. The phosphorylation of serine 328 was appeared 8 h after etoposide treatment and significantly increased in a time-dependent manner, and the timing of this increase was consistent with that of the interaction between cyclin A and Cdk2 (Fig. 3A, B). In addition, the etoposide-induced phosphorylation of Rad9 at serine 328 was completely inhibited in HeLa cells that were co-treated with roscovitine (Fig. 3C). However, serine 277 and serine 336 showed only moderate phosphorylation in etoposide-treated cells (Fig. 3-A). To provide further evidence that serine 328 of Rad9 can be phosphorylated by cyclin A-Cdk2, we performed an in vitro kinase assay. Cyclin A-Cdk2 was immunoprecipitated using a Cdk2 antibody from etoposide-treated HeLa cells and incubated with recombinant GST-Rad9 or GST-Rad9-S328A, a mutant version of Rad9, which is resistant to phosphorylation at serine 328. Immunoblotting analyses using phospho-specific antibodies against phospho328-Rad9 showed that Rad9 was phosphorylated at serine 328 and this phosphorylation was disappeared in the Rad9-S328A (Fig. 3D). These findings demonstrate that cyclin A-Cdk2 phosphorylates Rad9 at serine 328 in etoposide-treated apoptotic HeLa cells.

To determine the functional effect of the cyclin A-Cdk2-induced phosphorylation of Rad9 at serine 328 in HeLa cell apoptosis, we first investigated the caspase activation pathway in etoposide-treated HeLa cells. The activation kinetics of the caspases revealed that the activities of initiator caspase-9 and effector caspase-3/7 were up-regulated in cells treated with etoposide for 12 h, whereas caspase-6 activity remained unchanged until 24 h of treatment (Fig. 4A). The immunoblotting analysis showed that caspase-9 was cleaved to yield catalytically active forms after 12 h, whereas caspase-6 cleavage occurred after 24 h (Fig. 4B). Thus, the caspase cascade was initiated by the proteolytic activation of the initiator caspase-9 but not of the initiator caspase-6 in the process of etoposide-induced apoptosis in HeLa cells. Further study of the apoptosis pathway showed that cytochrome c was released from the mitochondria to the cytosol after 8 h of etoposide treatment (Fig. 4C). These findings indicate that etoposide induces HeLa cell apoptosis through mitochondria-mediated caspase-9 activation pathway.

The Phosphorylation of serine 328 up-regulates Rad9 Translocation from the Nucleus to the Mitochondria

To determine whether Rad9 phosphorylation regulates the mitochondria-mediated activation of caspase-9, we examined the distribution of Rad9 and of serine 328-phosphorylated Rad9 in etoposide-treated HeLa cells. Immunoblot analysis showed that Rad9 was translocated from the nucleus to the mitochondria in cells that were treated for 8 h. The serine 328-phosphorylated form of Rad9 appeared in the mitochondrial fraction after 8 h of treatment and gradually increased afterwards (Fig. 5A, B). Immunofluorescence analysis also showed that Rad9 was translocated from the nucleus to mitochondria in etoposide-treated HeLa cells (Fig. 5C). The timing of Rad9 phosphorylation at serine 328 upon etoposide treatment coincided well with that of the interaction of Rad9 with cyclin A-Cdk2 and that of the occurrence of mitochondrial Serine 328 phosphorylated Rad9 in HeLa cells. These findings suggest that the phosphorylation of Rad9 at serine 328 promotes the translocation of Rad9 from the nucleus to mitochondria in etoposide-treated HeLa cells.

To provide further evidence for the pro-apoptosis function of Rad9 we silenced its expression in HeLa cells. The specific inhibition of Rad9 using RNAi technology largely reduced the activation of caspase-3/7 and caspase-9 in etoposide-treated HeLa cells (Fig. 5D). Taken together, these results suggest that the cyclin A-Cdk2-mediated phosphorylation of Rad9 is crucial for the apoptosis progression.
To test whether the phosphorylation of Rad9 by cyclin A-Cdk2 promotes apoptosis, HeLa cells were co-transfected with pCMV-GFP, pCS4-Rad9, and pCMV-Cyclin A or pCMV-Cdk2-dn. The transfected cells were distinguished from untransfected cells on the basis of GFP expression. At 24 h after transfection, cell morphology was examined in the transfected cells. Approximately 35% of the Rad9-transfected cells displayed apoptotic morphology (including cell rounding and membrane blebbing), and 51% of the cyclin A-transfected cells exhibited this morphology. In contrast, only 15–20% of the cyclin A-transfected cells exhibited apoptotic morphology (Fig. 6A). We examined the activity of effector caspase-3/7 and the cleavage of PARP under...
the same experimental conditions. Caspase-3/-7 activity was elevated in the Rad9-transfected cells and further elevated in the cells co-transfected with Rad9 and cyclin A. The immunoblotting analysis showed that PARP cleavage occurred in the Rad9-transfected cells and was enhanced in the cells co-transfected with cyclin A and Rad9 (Fig. 6B).

Rad9 has been reported to contain a BH3-like region that can interact with the anti-apoptotic Bcl-2 family proteins, Bcl-2 or Bcl-
XL, and thereby promote apoptosis [26]. To determine whether the phosphorylation of Rad9 at serine 328 by cyclin A-Cdk2 regulates the interaction between Rad9 and Bcl-2 or Bcl-xL, we co-transfected HeLa cells with pCS4-myc-Rad9 and pCMV-Cyclin A or pCMV-Cdk2-dn and examined the interaction between Rad9 and Bcl-2 or Bcl-xL. After 36 h of transfection, the cells were immunoprecipitated with an anti-myc antibody, and the immunoprecipitates were analyzed by immunoblotting with antibodies against Cdk2, cyclin A, Bcl-2, and Bcl-xL. Rad9 was found to interact with Cdk2, cyclin A, Bcl-2, and Bcl-xL. The amount of Bcl-xL that was associated with the Rad9 complex was significantly increased in cyclin A co-transfected cells and was lower in Cdk2-dn co-transfected cells than in the cells transfected with Rad9 alone (Fig. 6C). Immunoblot analysis showed that the phosphorylation of Rad9 at serine 328 was dramatically increased in cyclin A co-transfected cells, and newly appeared in Cdk2-dn co-transfected cells (Fig. 6C). Next, we examined mitochondrial Bax translocation in Rad9 overexpressed HeLa cells. As shown in Fig. 6C, we found that Bax significantly translocated to mitochondria in Cyclin A co-transfected HeLa cells, whereas this translocation was dramatically reduced by Cdk2-dn transfection (Fig. 6C). Taken together, these results suggest that the cyclin A-Cdk2-mediated phosphorylation of Rad9 is crucial for the interaction of Rad9 with Bcl-xL and subsequent apoptosis progression.

Rad9S328A Promotes Apoptosis Less Efficiently than does Rad9

To test the hypothesis that the phosphorylation of Rad9 at serine 328 promotes its pro-apoptotic activities in HeLa cells, we examined the effect of the ectopic expression of Rad9S328A, a mutant version of Rad9 that is resistant to cyclin A-Cdk2 phosphorylation, on the induction of apoptosis. Apoptotic morphology was observed in 33% and 50% of the Rad9-transfected cells but in only 23% and 40% of the Rad9S328A-transfected cells 24 h and 48 h post transfection, respectively (Fig. 7A). Finally, we tested whether Rad9 phosphorylation at serine 328 regulates the interaction of Rad9 with Bcl-2 or Bcl-xL under the same experimental conditions. The immunoblot analysis of immunocomplexes that were immunoprecipitated with anti-myc
antibody showed that the disphosphorylation of Rad9 at serine 328 greatly reduced the interaction of Rad9 with Bcl-xL but not with Bcl-2 (Fig. 7B). Taken together, these findings suggest that cyclin A-Cdk2 regulates Rad9-mediated apoptosis by phosphorylating Rad9 at serine 328 in HeLa cells.

Discussion

Four major observations were made in this study: (i) Rad9, a member of the BH3-only protein subfamily, can be phosphorylated by cyclin A-Cdk2 in vitro and in vivo; (ii) cyclin A-Cdk2 phosphorylates Rad9 at serine 328 during etoposide-induced apoptosis in HeLa cells; (iii) the up-regulation of cyclin A-Cdk2 activity enhances Rad9-induced apoptosis by phosphorylating Rad9 at serine 328; and (iv) the phosphorylation of Rad9 at serine 328 is required for the interaction of Rad9 with Bcl-xL.

Rad9 contains a BH3-like region and promotes apoptosis in ara-C-treated U937 cells [28,29]. Previous studies have shown that cyclin A-Cdk2, a cell cycle-regulated protein kinase, can be activated by various stimuli and plays key roles in apoptotic processes [3–9]. We investigated whether cyclin A-Cdk2 phosphorylates Rad9 during apoptosis. We chose to use etoposide-induced apoptosis in HeLa cells as an experimental system because cyclin A-Cdk2, but not cyclin B-Cdk2, is selectively activated in this process, and this activation is essential for the progression of apoptosis at an early stage [4]. The intracellular levels of cyclin A

Figure 4. Etoposide induces apoptosis through caspase-9 and caspase-3 activation, mediated by mitochondrial cytochrome c release. HeLa cells were treated with etoposide (50 μg/mL) for the indicated times. (A) Cell-free caspase-3, -8, and -9 activities were analyzed using specific substrates (Ac-DEVD-AFC, Ac-IETD-AFC, and Ac-LEHD-AFC, respectively). (B) The cells were analyzed by immunoblotting for caspase-8 and caspase-9. (C) Equal amounts of proteins from the cytosolic fraction were resolved by SDS-PAGE and analyzed by immunoblotting using antibodies against cytochrome c and α-tubulin.

doi:10.1371/journal.pone.0044923.g004
The activation of cyclin A-Cdk2 (Fig. 2A) and the electrophoretic mobility shift of Rad9 were all upregulated in etoposide treated HeLa cells. In addition, the coimmunoprecipitation analysis showed that Rad9 interacted with cyclin A and Cdk2 in a time-dependent manner following etoposide treatment (Fig. 3B). These findings suggest that the selective up-regulation of cyclin A-Cdk2 may be associated with Rad9 phosphorylation during etoposide-induced apoptosis in HeLa cells.

Since Rad9 is a checkpoint protein, it has been shown to be phosphorylated by several kinase including ataxia-telangiectasia-mutated (ATM), PKCδ and c-Abl upon genotoxic stimuli [28,29,31]. Interestingly in our study, the phosphorylation form of Rad9 was observed as early as 4 h after etoposide treatment (Fig. 2B), while the interaction between Cdk2 with Rad9 was occurred after 8 h treatment (Fig. 3B) in HeLa cells. We then suggest that the early stage (at 4h) phosphorylation of Rad9 maybe not driven by cyclin A-Cdk2.

Rad9 contains nine potential consensus Cdk2 phosphorylation sequences (S/TPXK/R) [32], but an in vitro kinase assay showed that only three potential phosphorylation sites (serine 277, serine 328, and serine 336) were phosphorylated by cyclin A-Cdk2 (data not shown). We analyzed the phosphorylation at these three serine residues in etoposide-treated HeLa cells using phospho-specific antibodies. The phosphorylation of Rad9 at serine 328 was observed at 8h after the etoposide treatment and subsequently increased significantly in a time-dependent manner. In contrast, serine 277 and serine 336 of Rad9 were only moderately phosphorylated under the same experimental conditions.

![Figure 5](image-url)

**Figure 5. Serine 328-phosphorylated Rad9 is translocated from the nucleus to the mitochondria during etoposide-induced apoptosis in HeLa cells.** HeLa cells were treated with etoposide (50 μg/mL) for the indicated times. Equal amounts of protein from the nuclear fractions (A), and mitochondrial fractions (B) were resolved by SDS-PAGE and analyzed by immunoblotting using antibodies against Rad9, phosphorylated-Rad9, PCNA, α-tubulin, and COX IV. (C) The cells were treated with etoposide (50 μg/mL) for 20 h. The cells were fixed and stained with anti-Rad9 and anti-COX IV antibodies and analyzed by confocal microscopy using appropriate filters for the visualization of green, red, or combined fluorescence resulting from the presence of FITC and rhodamine molecules. Bar, 20 μm. (D) HeLa cells were transfected with negative control or Rad9 siRNA followed by the treatment with etoposide (50 μg/mL) for 20 h. Top: Cell extracts were assayed for caspase-3 and caspase-9 activities using the specific substrates Ac-IETD-AFC and Ac-DEVD-AFC (* p<0.05). Bottom: The contents of Rad9 and Actin in cell lysates were examined by immunoblotting.

doi:10.1371/journal.pone.0044923.g005
The timing of Rad9 phosphorylation at serine 328 upon etoposide treatment coincided well with that of the interaction of Rad9 with cyclin A-Cdk2. Furthermore, the phosphorylation of Rad9 at serine 328 was blocked by the addition of roscovitine to the culture medium (Fig. 3C). These findings indicate that specifically activated cyclin A-Cdk2 kinase phosphorylates endogenous Rad9 at serine 328 during etoposide-induced apoptosis in HeLa cells.

A previous study suggested that etoposide-induced apoptosis in head and neck carcinoma cells is dependent on mitochondria-...
mediated caspase-9 activation [33]. Similarly, we observed that caspase-9, but not caspase-8, is activated in the early stages of etoposide-induced apoptosis in HeLa cells (Fig. 4A, B). Consistently with this observation, cytochrome c was released from mitochondria to the cytosol 8h after etoposide treatment (Fig. 4C), indicating that etoposide-induced apoptosis in HeLa cells is initiated by a mitochondrial pathway.

A previous report showed that the overexpression of Rad9 induces apoptosis and that this apoptosis can be blocked by Bcl-2 or Bcl-xL [26]. In the present study, cell fractionation and immunofluorescence analyses showed that Rad9 translocated from the nucleus to the mitochondria in etoposide-treated HeLa cells (Fig. 5A–C). Almost all of the serine 328-phosphorylated Rad9 was found in the mitochondria, suggesting that Rad9 phosphorylation at serine 328 is associated with the pro-apoptotic function of Rad9 in HeLa cells. Importantly, the phosphorylation of Rad9 at serine 328, the translocation of Rad9 to mitochondria, and the cytochrome c release occurred at the same time period in etoposide treated HeLa cells. In addition, the communoprecipitation analysis showed that Rad9 interacted with Bcl-xL in a time-dependent manner following etoposide treatment (Fig. S1). We therefore hypothesized that Rad9 phosphorylation at serine 328 might regulate the caspase-9 activation pathway that was initiated by mitochondrial cytochrome c release.

Rad9-induced apoptosis was significantly (p<0.005) enhanced by the elevation of cyclin A-Cdk2 activity through the overexpression of cyclin A (Fig. 6A, B). The phosphorylation of Rad9 at serine 328 and the interaction between Rad9 with Bcl-xL were dramatically increased by cyclin A overexpression and completely inhibited by Cdk2-dn overexpression (Fig. 6C). In addition, the pro-apoptotic activity of Rad9S328A was significantly lower than that of wild-type Rad9 (Fig. 7A). The amount of Bcl-xL associated with the Rad9 complex was much lower in the Rad9S328A-transfected cells than in the Rad9-transfected cells. Interestingly, the amount of Bcl-2 associated with the Rad9 complex was almost equal in these two backgrounds (Fig. 7B). All these findings indicate that cyclin A-Cdk2 induced phosphorylation of Rad9 at serine 328 promotes the interaction with Bcl-xL, but not Bcl-2, and thereby triggers the apoptotic process.

Cyclin A overexpression enhanced the apoptosis in the presence of Rad9-S328A, but still less than that in the presence of Rad9-wt (Fig. S2). We suggested that there might be other phosphorylation sites involved in the pro-apoptotic function of Rad9. In addition, part of overexpressed Rad9-wt and Rad9-S328A translocated to mitochondria, and the amount of Rad9-S328A was much less than that of Rad9-wt (Fig. S3). The partial suppression of Rad9-induced apoptosis by Cdk2-dn and the remaining pro-apoptotic activity of Rad9S328A observed in present study (Fig. 6 and 7) may result from the interaction between the serine 328 dephosphorylated form of Rad9 and Bcl-2. These possibilities will be examined in future studies.

It will also be important to determine whether cyclin A-Cdk2 directly activates other apoptosis regulatory proteins in a phosphorylation-dependent manner and whether serine 328 of Rad9 is the target of other protein kinases that transduce apoptotic signals. In this study, we observed that the phosphorylation of Rad9 at serine 328 triggers the interaction of Rad9 with Bcl-xL. The conformational changes upon this phosphorylation and the consequent interaction activity of Rad9 will be studied by structure analysis in future.

To provide further evidence for the apoptosis mediating activity of endogenous Rad9, we silenced its expressions using RNAi technology. The caspase-cascade was largely inhibited in Rad9 down regulated cells upon etoposide treatment (Fig. 5D).
The Bcl-2 family member Bax translocates from the cytosol to mitochondria, where it oligomerizes and permeabilizes the mitochondrial outer membrane to promote apoptosis [34,35]. Previous study has shown that Cdk2 activity is involved in the mitochondrial translocation of Bax in etoposide-induced HeLa cell apoptosis [4]. In present study, we also observed that Bax translocated to mitochondria in Rad9-induced apoptosis of HeLa cells, and this translocation was dramatically inhibited by overexpression of Cdk2-dn (Fig. 6C). Previous study has shown that Bcl-xL interacts with Bax to enhance its mitochondrial translocation by disturbing Bcl-xL-mediated Bak translocation from the mitochondria into the cytosol in normal cells [36], thus, we suggested that the interaction of Rad9 with Bcl-xL might enhance the mitochondrial translocation of Bax by disturbing Bcl-xL-mediated Bak translocation in Rad9 overexpressed HeLa cells.

The present findings suggest that Rad9 is a novel substrate of cyclin A-Cdk2 and that it is phosphorylated at serine 328 during etoposide-induced apoptosis in HeLa cells. The phosphorylation of Rad9 at serine 328 is important for Rad9’s functions, including its translocation from the nucleus to the mitochondria, its interaction with Bcl-xL, and its consequent pro-apoptotic activity.

Materials and Methods

Materials

Etoposide and roscovitine were purchased from Sigma (St. Louis, MO). [γ-32P]ATP was purchased from Amersham Pharmacia Biotech. The caspase substrates Ac-DEVDEV-AMC, Ac-DEVD-AMC, and Ac-LEHD-AMC were purchased from Calbiochem (Darmstadt, Germany). The Mitochondria Isolation Kit was purchased from Pierce (Rockford, IL). Antibodies against poly(-ADP-ribose) polymerase (PARP), Cdk2, cyclin A, PCNA, cytochrome c, y-tubulin, and β-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against caspase-8, caspase-9, Bcl-xL, Bcl-2, and Cox IV were purchased from Cell Signaling Technology (Danvers, MA). The antibody against Rad9 was purchased from Abcam (Cambridge, UK). Antibodies against pS328, pS277, and pS336 were purchased from Abnova (Walnut, CA). All other drugs and chemicals were purchased from Sigma.

Methods

Cell culture and etoposide treatment.

HeLa cells were maintained as monolayer cultures in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) heat-inactivated calf serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. Etoposide was added at a final concentration of 50 μg/mL to log phase cell cultures for the indicated time periods. Both floating and adherent cells were harvested for immunoblotting and caspase activity assays.

Preparation of total protein in cell lysates.

The cells were washed with ice-cold PBS and solubilized in a lysis buffer containing 20 mMTris-HCl (pH 7.5), 0.5% Triton X-100, 2 mM MgCl₂, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 2 mg/mL leupeptin, 2 mg/mL pepstatin A, 2 mg/mL antipain, and 1 mM PMSF. After incubation on ice for 1 h, the insoluble materials were removed by centrifugation at 12,000 g for 15 min, and the supernatants were used for immunoblotting experiments.

Transient transfection analysis of apoptosis in transfected cells.

HeLa cells were transfected and prepared using PolyFect Transfection Reagent (Qiagen, Valencia, CA) according to the manufacturer’s instructions. In the experiments shown in Fig. 1B, HeLa cells were co-transfected with 0.3 μg pCS4-Rad9 and 1.5 μgCMV-Cyclin A and/or 0.3 μg pCMV-cdk2-dn per well in 6-well plates. In the experiments shown in Fig. 6, HeLa cells were transfected with 0.3 μgCMV-GFP and 0.6 μgCMV-Cyclin A or 0.6 μg pCMV-cdk2-dn and/or 1.2 μg pCS4-Rad9 per well. In the experiments shown in Fig. 7, each well was transfected with 0.5 μgCMV-GFP and 1.5 μg pCS4-Rad9 wt or 1.5 μg pCS4-Rad9-S328A. After transfection for 24, 36, or 48 h, the cells were examined by fluorescence microscopy (Olympus, Tokyo, Japan). The extent of apoptosis was determined by counting GFP-expressing cells with blebbing or normal morphology in 3 randomly selected fields (80–100 cells per field).

Caspase assay.

The cell-free caspase assay was performed by incubating 50 μg of cell lysate with 200 nM Ac-DEVDE-AMC (for caspase-3), Ac-LEHD-AMC (for caspase-8), or Ac-LEHD-AMC (for caspase-9) in a reaction buffer containing 20 mMHEPES, pH 7.4, 100 mMNaCl, 10 mMMDT, 0.1% CHAPS, and 10% sucrose at 37°C for 1 h. The reaction was monitored by fluorescence emission at 505 nm and excitation at 405 nm.

Preparation of subcellular fractions.

Nuclear protein extracts were prepared as described previously [4]. The cells were resuspended in homogenization buffer (250 mM sucrose, 20 mMHEPES, 1.5 mM MgCl₂, 0.1 mM EDTA, 1 mM EGTA, 1 mM DTT, and 0.1 mM PMSF, pH 7.5). The cells were then homogenized with a Dounce homogenizer, and the homogenates were centrifuged at 4°C and 1000 x g for 5 min to pellet the nuclear fraction. Mitochondria extracts were prepared using the Mitochondria Isolation Kit (Pierce) for cultured cells according to the manufacturer’s instructions. Isolated nuclei and mitochondria were solubilized in a lysis buffer containing 20 mMTris-HCl (pH 7.5), 150 mMNaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 2 mM MgCl₂, 1 mMMDT, 1 mMEGTA, 50 mM b-glycerol phosphate, 25 mMNaF, 1 mM Na₃VO₄, 2 mg/mL leupeptin, 2 mg/mL pepstatin A, 2 mg/mL antipain, and 1 mM PMSF. After incubation on ice for 1 h, the insoluble materials were removed by centrifugation at 12,000 x g for 15 min, and the supernatants of the nuclear and mitochondrial extracts contained the total protein.

Immunoblot analysis.

An aliquot (50 μg protein) of each sample was resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and electro-transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, MA). The membrane was blocked with 5% nonfat milk and probed with a specific primary antibody. The membrane was then washed and incubated with horseradish peroxidase-coupled anti-mouse or anti-rabbit IgG, and the protein bands were visualized by enhanced chemiluminescence (ECL, Amersham Biosciences, Piscataway, NJ).

Expression and purification of the GST-Rad9 fusion protein.

pGEX-4T-1-Rad9 was transformed into E. coli BL21. The transformed E. coli were cultured in 200 mL LB medium containing 100 μg/mL ampicillin at 37°C until the A₆₀₀ reached 0.5, and then protein expression was induced by adding isopropyl-β-D-1-Thiogalactopyranoside (IPTG) to a final concentration of 0.2 mM at 25°C for 16 h. The GST-Rad9 fusion protein was purified using a GST-glutathione affinity system (GE) according to the manufacturer’s instructions. Purified GST-Rad9 was used as the substrate for the in vitro kinase assay.

Immunoprecipitation and in vitro kinase assay.

An aliquot (200 μg protein) of each cell extract was precleared with protein A-agarose beads, and the supernatant was incubated with anti-Cdk2 antibody for 4 h. The Cdk2 immunocomplexes were collected after incubation with protein A-agarose beads for 2 h. The immunocomplexes were washed three times with immunoprecipitation lysis buffer and twice with kinase assay buffer containing 50 mMTris pH 7.5, 10 mM MgCl₂, 1 mM di-thiothreitol, 1 mMMDT, 50 mM β-glycerol phosphate, 25 mMNaF,
0.1 mM Na3VO4, 1 μg/mL leupeptin, 1 μg/mL pepstatin A, 1 μg/mL antipain, and 1 mM PMSF. The immunocomplexes were then incubated for 15, 30, or 60 min at 30°C in 50 μL of the kinase assay buffer supplemented with purified recombinant GST-Rad9 (Fig. 1A) or 1 μg of histone H1 (Upstate Biotecnology) (Fig. 2D). 10 mM [γ-32P] ATP (10 μCi), 5 mM/L protein kinase A inhibitor, and 20 mM/L EGTA. The reaction was resolved by 12% SDS-PAGE, and the Cdk2 kinase activities were determined by autoradiography.

**Immunofluorescence.** The cells were cultured overnight on sterile glass cover slips in 6-well plates. The cells were treated with etoposide for 20 h to induce apoptosis and subsequently fixed with 4% formaldehyde for 10 min, rinsed three times with PBS, and permeabilized with 0.1% Triton X-100 for 15 min. The cells were then rinsed three times with PBS, blocked for 30 min with blocking solution (5% BSA in 0.1% Triton X-100), and then rinsed again three times with PBS, blocked for 30 min with blocking solution and incubated in secondary antibody (FITC-conjugated rabbit polyclonal anti-Rad9 (1:200) and mouse monoclonal anti-Actin). The cells were washed twice in PBS and then mounted by inverting onto mounting medium on glass slides. The slides were stored at 4°C and analyzed by fluorescence confocal microscopy (Olympus).

**RNA Interference.**

3 × 10²² HeLa cells in six-well dishes were transfected with a final concentration of 50 nM small interfering RNA (siRNA) duplexes using HiPerFect Transfection Reagent (Qiagen, Valencia, CA), according to the manufacturer's instruction. siRNA duplexes for Rad9 and controlled siRNA were from Bioneer Co. (Daejeon, Korea). siRNA sense sequences were shown as follows: the siRNA sequence targeting human Rad9, 5'-GAAUUCCUAGGC-CUUGGAd(TdT)3'; the negative control sequence, 5'-CCUACGCCAUUUCGU(tdT)3'. After incubation for 24 h, cells were treated with etoposide (50 μg/mL) for 20 h. Finally, the total protein in cell lysates was prepared for caspase-3, caspase-9 activities assay and immunoblotting analysis of Rad9 and β-Actin.

**Supporting Information.**

**Figure S1** HeLa cells were treated with etoposide (50 μg/mL) for the indicated times. Lysates from treated cells were subjected to immunoprecipitation with anti-Rad9 antibody and immunoblotting with antibodies against Bcl-xL and Rad9. (TIF)

**Figure S2** HeLa cells were co-transfected with pCMV-GFP, pCS4-myc-Rad9-S328A, pCMV-Cyclin A, or pCMV-Cdk2-dn. Top: Bright-field and GFP fluorescence of the same field (x100) of transfected cells. Bottom: GFP-expressing cells with blebbing or normal morphology were counted. The extent of apoptosis was determined by counting GFP-expressing cells with blebbing or normal morphology in three randomly selected fields (80–100 cells per field). The average numbers in three different fields from two independent experiments are shown. Bar, 50 μm. (TIF)

**Figure S3** HeLa cells were transfected with pCS4, pCS4-Myc-Rad9-wt, or pCS4-Myc-Rad9-S328A. Equal amounts of protein from mitochondrial fractions were resolved by SDS-PAGE and analyzed by immunoblotting using antibodies against Rad9 and COX IV. (TIF)

**Author Contributions.**

Conceived and designed the experiments: Y-HJ. Performed the experiments: ZZ. Analyzed the data: ZZ. Contributed reagents/materials/analysis tools: KH DZ DJ YL CS. Wrote the paper: Y-HJ. Edited the manuscript: Y-HH.

**References.**

1. Morgan DO (1995) Principles of CDK regulation. Nature 374: 131–134.
2. Calbo J, Serna C, Garriga J, Graña X, Mazo A (2004) The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity. Cell Death and Differentiation 11: 1055–1065.
3. Hirohara K, Pippin J, Blonski M, Roberts J, Shankland S (2002) The subcellular localization of cyclin dependent kinase 2 determines the fate of mesangial cells: role in apoptosis and proliferation. Oncogene 21: 1750–1758.
4. Choi J-S, Shin S, Jin YH, Yim H, Koo K-T, et al. (2007) Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. Apoptosis 12: 1229–1241.
5. Bastin-Coyette L, Cardoen S, Malc C, de Viron E, Arts A, et al. (2011) Nuclearside analogs induce proapoptotic down-regulation of p21 in chronic lymphocytic leukemia cell lines. Biochemical Pharmacology 81: 506–509.
6. Levkau B, Koyama H, Raines EW, Clurman BE, Herren B, et al. (1998) Cleavage of p21Cip1/Waf1 and p27Kip1 Mediates Apoptosis in Endothelial Cells through Activation of Cdk2: Role of a Caspase Cascade. Molecular Cell 1: 553–563.
7. Jin YH, Yoo KJ, Lee YH, Lee SK (2000) Caspase 3-mediated Cleavage of p21WAF1/CIP1/Associated with the Cyclin A–Cyclin-dependent Kinase 2 Complex Is a Prerequisite for Apoptosis in SK-HEP-1 Cells. Journal of Biological Chemistry 275: 30256–30263.
8. Jin YH, Yoon HS, Lee SK, Jeong SH, Lee SK (2005) Cdk2 activity is associated with depolarization of mitochondrial membrane potential during apoptosis. Biochemical and Biophysical Research Communications 305: 974–980.
9. Guo X-X, Kim H, Li Y, Yin H, Lee SK, et al. (2011) Cdk2 acts upstream of mitochondrial permeability transition during paclitaxel-induced apoptosis. Protein & Cell 2: 541–553.
10. Gross A, McDonnell JM, Korsmeyer SJ (1999) Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899–1911.
11. Adams JM, Cory S (1990) The Bcl-2 Protein Family: Arbiter of Cell Survival. Science 281: 1322–1326.
12. Coultas L, Strasser A (2003) The role of the Bcl-2 protein family in cancer. Seminars in Cancer Biology 13: 115–123.
13. Zhao L, He F, Liu H, Zhu Y, Tian W, et al. (2012) Natural Diterpenoid Compound Elevates Expression of Bim Protein, Which Interacts with Antiapoptotic Protein Bcl-2, Converting It to Proapoptotic Bcl-2-like Molecule. The Journal of Biological Chemistry 287: 1054–1063.
14. Zhu Y, Li M, Wang X, Jin H, Liu S, et al. (2011) Caspase cleavage of cytochrome c disrupts mitochondrial function and enhances cytochrome c release. Cell Research: 1–15.
15. Murray MJ, Carr MA, Lehmann RA, Watts ZF (1991) Cloning and characterisation of the rad9 DNA repair gene from Schizosaccharomyces pombe. Nucleic Acids Research 19: 3525–3531.
16. Lieberman HR, Yin Y (2004) A Novel Function for Human Rad9 Protein as a Transcriptional Activator of Gene Expression. Cell Cycle 3: 1008–1010.
17. Greer Card DA, Sierant ML, Davey S (2010) Rad9A Is Required for G2 Decatenation Checkpoint and to Prevent Endoreduplication in Response to Topoisomerase II Inhibition. Journal of Biological Chemistry 285: 15653–15661.
18. Lieberman HB (2006) Rad9, an evolutionarily conserved gene with multiple functions for preserving genomic Integrity. Journal of Cellular Biochemistry 97: 690–697.
19. Lieberman HB, Hopkins KM, Naas M, Demetrack D, Davey S (1996) A human homolog of the Schizosaccharomyces pombe rad9 checkpoint control gene. Proc Natl Acad Sci USA 93: 13890–13895.
20. Hirai I, Wang G (2002) A Role of the C-terminal Region of Human Rad9 (hRad9) in Nuclear Transport of the hRad9 Checkpoint Complex. Journal of Biological Chemistry 277: 25722–25727.
21. St-Onge RP (2003) A Role for the Phosphorylation of hRad9 in Checkpoint Signaling. Journal of Biological Chemistry 278: 26620–26628.
22. Burtelev MA, Kaatmann SH, Karmitz LM (2000) Retention of the Human Rad9 Checkpoint Complex in Extraction-resistant Nuclear Complexes after DNA Damage. Journal of Biological Chemistry 275: 26345–26348.
23. Volkmer E, Karnitz LM (1999) Human Homologs of Schizosaccharomyces pombe Rad1, Hus1, and Rad9 Form a DNA Damage-responsive Protein Complex. Journal of Biological Chemistry 274: 567–570.

24. Parrilla-Castellar ER, Arlander SJH, Karnitz L (2004) Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex. DNA Repair 3: 1009–1014.

25. Onge RPS, Udell CM, Casselman R, Davey S (1999) The Human G2 Checkpoint Control Protein hRAD9 Is a Nuclear Phosphoprotein That Forms Complexes with hRAD1 and hHUS1. Molecular Biology of the Cell 10: 1985–1993.

26. Komatsu K, Miyashita T, Hang H, Hopkins KM, Zheng W, et al. (2000) Human Homologue of S. Pombe Rad9 Interacts with Bcl-2/Bcl-xL and Promotes Apoptosis. Nat Cell Biol 2: 1–6.

27. Komatsu K, Hopkins KM, Lieberman HR, Wang H-G (2000) Schizosaccharomyces pombe Rad9 contains a BH3-like region and interacts with the anti-apoptotic protein Bcl-2. FEBS Letters 461: 122–126.

28. Yoshida K, Wang H-G, Miki Y, Kufe D (2003) Protein kinase Cd is responsible for constitutive and DNA damage-induced phosphorylation of Rad9. The EMBO Journal 22: 1431–1441.

29. Yoshida K, Komatsu K, Wang HG, Kufe D (2002) c-Abl Tyrosine Kinase Regulates the Human Rad9 Checkpoint Protein in Response to DNA Damage. Molecular and Cellular Biology 22: 3292–3300.

30. Lieberman HB, Bernstock JD, Broustas CG, Hopkins KM, Leloup C, et al. (2011) The role of RAD9 in tumorigenesis. Journal of Molecular Cell Biology 3: 39–43.

31. Rossi R, Lidonnici MR, Samuela Souza, Biamonti G, Montecucco A (2006) The Dispersal of Replication Proteins after Etoposide Treatment Requires the Cooperation of Nbs1 with the Ataxia Telangiectasia Rad3-Related/Chk1 Pathway. Cancer Research 66: 1675–1683.

32. Holmes JK, Solomon MJ (1996) A Predictive Scale for Evaluating Cyclin-dependent Kinase Substrates. The Journal of Biological Chemistry 271: 25240–25246.

33. Liu J, Uematsu H, Tsuchida N, Ikeda M-A (2011) Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Molecular Cancer 10: 93.

34. Gross A, Jockel J, C.Wei M, J.Korsmeyer S (1998) Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. The EMBO Journal 17: 3876–3885.

35. Wolter KG, Hsu Y-T, Smith CL, Nechushtan A, Xi X-G, et al. (1997) Movement of Bax from the Cytosol to Mitochondria during Apoptosis. The Journal of Cell Biology 139: 1281–1292.

36. Edlich F, Banejee S, Suzuki M, Cleland Megan M, Arnoult D, et al. (2011) Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol. Cell 145: 104–116.